Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mark Velleca"'
Autor:
Kevin S. Currie, J. Andrew Whitney, Julie DiPaolo, Tarif Awad, Shan Jiang, Dapeng Qian, Arun Ramamurthy, Mark Velleca, Johnny Peppers, Scott Alderucci, Xiaobing Qian
Publikováno v:
ASSAY and Drug Development Technologies. 5:49-64
The importance of protein kinases as a major class of drug targets across multiple diseases has generated a critical need for technologies that enable the identification of potent and selective kinase inhibitors. Bruton's tyrosine kinase (Btk) is a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238c9246f2d8807b40ffe7b82e37ca21
https://doi.org/10.1089/adt.2006.032
https://doi.org/10.1089/adt.2006.032
Publikováno v:
Current Proteomics. 1:83-102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a9be122589e212138fcff91ee63a56a
https://doi.org/10.2174/1570164043379433
https://doi.org/10.2174/1570164043379433
Publikováno v:
Current Drug Discovery Technologies. 1:13-26
While standard transgenic and knockout mouse technologies have provided a wealth of information for target selection and validation, there have been great advances in using more sophisticated modeling techniques to achieve temporal and spatial regula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1813f07d2533b7b505b55d605f6cb583
https://doi.org/10.2174/1570163043484806
https://doi.org/10.2174/1570163043484806
Autor:
Mark Velleca, Kevan M. Shokat
Publikováno v:
Drug discovery today. 7(16)
Concurrent advances in both high-throughput chemistry and genomics have given rise to the field of chemical genetics as a discipline for elucidating and validating drug targets, and generating novel therapeutics. Indeed, chemical genetic approaches t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1cf61a20b0c45dca3eb3c77db59b5d
https://pubmed.ncbi.nlm.nih.gov/12546853
https://pubmed.ncbi.nlm.nih.gov/12546853
Autor:
Scott Roberts, Velizar T. Tchernev, Zhimin Zhou, Minjuan Wang, Quiping Shu, Isabelle Laroche, Jason Christiansen, Mark Velleca, Barry Schweitzer, Weiping Shao, Brian Grimwade, Qin Fu, Stephen F. Kingsmore
Publikováno v:
Nature biotechnology. 20(4)
Fluorescent-sandwich immunoassays on microarrays hold appeal for proteomics studies, because equipment and antibodies are readily available, and assays are simple, scalable, and reproducible. The achievement of adequate sensitivity and specificity, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b894b75c820041f36ecae9c9142152f6
https://pubmed.ncbi.nlm.nih.gov/11923841
https://pubmed.ncbi.nlm.nih.gov/11923841
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 91(9)
Although the actions of insulin and a number of growth factors that signal via protein-tyrosine kinase receptors are believed to involve increased phosphorylation of key intracellular proteins, relatively few of the downstream phosphoproteins have be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245f3509be73ac5f48a315f81b2b3d60
https://pubmed.ncbi.nlm.nih.gov/8170978
https://pubmed.ncbi.nlm.nih.gov/8170978
Autor:
Sandip Gurav, Sanjeev Giri, Ravindranath Reddy Gilibili, Ramesh Mullangi, Mohd Zainuddin, Raman Govindrajan, Sherine Jeniffer, Mark Velleca, Srinivas Nuggehally
Publikováno v:
Cancer Research. 71:3286-3286
Objectives JI-101 is a novel orally active kinase inhibitor has shown potent in vitro and in vivo anticancer activity against a variety of cancer cell lines and xenografts It is currently entering phase II clinical development for the treatment of so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b75eeb966e5a59dc32a7d3b47ae58dd
https://doi.org/10.1158/1538-7445.am2011-3286
https://doi.org/10.1158/1538-7445.am2011-3286
Autor:
L. Miller, Michael S. Gordon, R. Mullangi, Mark Velleca, M. Sahu, Sunil Sharma, D. Brittelli, R. Govindarajan, Nuggehally R. Srinivas
Publikováno v:
European Journal of Cancer Supplements. 8:127
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a6f6a1f4b634824c64c570a15783e60
https://doi.org/10.1016/s1359-6349(10)72107-8
https://doi.org/10.1016/s1359-6349(10)72107-8
Autor:
Warren Stern, Sunil Sharma, Linda S. Miller, Nandhagopal N, Xiaobing Qian, David R. Brittelli, Scott A. Mitchell, Dapeng Qian, Sreesha Srinivasa, Michael S. Gordon, Udo Klein, Lisa Elkin, Raman Govindarajan, Thomas Stephen, Mark Velleca
Publikováno v:
Cancer Research. 70:17-17
Introduction JI-101 is a highly selective and potent angiogenesis inhibitor with unique EphB4 activity that distinguishes it from other agents in clinical development. We report the preclinical pharmacology and early clinical experience with this com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db0414bb2448ea9c41f7228708f9a7a8
https://doi.org/10.1158/1538-7445.am10-17
https://doi.org/10.1158/1538-7445.am10-17
Autor:
Dapeng Qian, Sunil Sharma, Linda Miller, Thomas Stephan, Raman Govindarajan, Mark Velleca, Warren Stern, Michael S. Gordon, Scott A. Mitchell, Udo Klein, Xiaobing Qian, David R. Brittelli, Sreesha Srinivasa, Lisa Elkin
Publikováno v:
Molecular Cancer Therapeutics. 8:B11-B11
Introduction: JI-101 is a highly selective and potent angiogenesis inhibitor with unique EphB4 activity that distinguishes it from other agents in clinical development. We report the preclinical pharmacology and early clinical experience with this co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38409d77acf79785863ac3743dc14ef2
https://doi.org/10.1158/1535-7163.targ-09-b11
https://doi.org/10.1158/1535-7163.targ-09-b11